Context Therapeutics (NASDAQ:CNTX) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Context Therapeutics (NASDAQ:CNTX) from a sell rating to a hold rating in a report issued on Saturday.

Other equities analysts have also recently issued research reports about the stock. HC Wainwright boosted their price objective on shares of Context Therapeutics from $4.00 to $5.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Jones Trading assumed coverage on Context Therapeutics in a report on Monday, December 22nd. They set a “buy” rating and a $7.00 target price for the company. D. Boral Capital reissued a “buy” rating and set a $9.00 price objective on shares of Context Therapeutics in a research report on Thursday, November 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Context Therapeutics in a report on Wednesday, January 21st. Seven investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $6.00.

Context Therapeutics Trading Down 9.2%

NASDAQ CNTX opened at $2.37 on Friday. Context Therapeutics has a 1-year low of $0.49 and a 1-year high of $2.85. The stock has a 50-day moving average of $1.43 and a 200-day moving average of $1.14. The firm has a market cap of $217.76 million, a PE ratio of -9.88 and a beta of 1.93.

Context Therapeutics (NASDAQ:CNTX) last posted its quarterly earnings results on Wednesday, November 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.01). As a group, equities research analysts forecast that Context Therapeutics will post -0.51 earnings per share for the current fiscal year.

Institutional Trading of Context Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of CNTX. Clear Harbor Asset Management LLC lifted its position in Context Therapeutics by 60.5% during the 3rd quarter. Clear Harbor Asset Management LLC now owns 92,804 shares of the company’s stock valued at $90,000 after acquiring an additional 35,000 shares during the period. Citadel Advisors LLC bought a new position in shares of Context Therapeutics during the third quarter valued at approximately $100,000. Finally, Vanguard Group Inc. lifted its holdings in shares of Context Therapeutics by 4.0% during the third quarter. Vanguard Group Inc. now owns 3,495,031 shares of the company’s stock valued at $3,387,000 after purchasing an additional 134,449 shares during the last quarter. 14.03% of the stock is owned by hedge funds and other institutional investors.

About Context Therapeutics

Context Therapeutics (NASDAQ: CNTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of precision therapies for genetically defined patient populations in oncology. The company’s research model centers on identifying novel targets and designing small-molecule and biologic candidates that address key drivers of tumor growth and resistance. Context Therapeutics leverages a biomarker-driven approach to maximize the probability of clinical response, tailoring its development programs to specific molecular subgroups within solid tumors.

With a pipeline advancing through early clinical trials, Context Therapeutics emphasizes strategic collaborations and academic partnerships to accelerate the translation of laboratory findings into patient-focused studies.